Clinical Trial Update: AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) [Phase 2]

View source ↗

Summary

Pfizer's axitinib (AG-013736) was studied in a Phase 2 trial in patients with poor-prognosis acute myeloid leukemia or myelodysplastic syndrome; results were po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: Pfizer | Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2012-03-19